Biogen Stock News

Is it time to buy a basket of biotech stocks?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced the CORAL Study in people with major depressive disorder (MDD) met the trial objectives, demonstrating a rapid and statistically significant reduction in depressive symptoms at Day 3 and over the 2-week treatment period, achieving the primary and key secondary endpoints. This significance was demonstrated at the first measured time point, Day 3, with zuranolone 50 mg co-init

All of them are directly related to Aduhelm.

NEW YORK, Feb. 15, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Biogen Inc. (NASDAQ: BIIB) alleging that the Company violated federal securities laws. Class Period: June 7, 2021 to January 11, 2022 Lead…

NEW YORK, Feb. 14, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation…

SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Biogen Inc. (NASDAQ: BIIB) investors with significant losses to submit your losses now . A securities fraud class action has been filed and certain investors may have valuable claims.

SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Biogen Inc. (NASDAQ: BIIB ) investors with significant losses to submit your losses now . A securities fraud class action has been filed and certain investors may have valuable claims. Class Period: June 7, 2021 – Jan. 11, 2022 Lead Plaintiff Deadline: April 8, 2022 Visit: www.hbsslaw.com/investor-fraud/BIIB Contact An Attorney Now: [email protected] 844-916-0895 Biogen Inc. (BIIB) Securities Class Action: The lawsuit focuses on Biogen''s and senior management''s statements leading up to- and after- the June 7, 2021 announcement that the FDA approved Biogen''s ADUHELM for the treatment of Alzheimer''s and the treatment''s annual price tag would be $56,000. According to the complaint, defendants made false and misleading statements and/or failed to disclose that: (1) Biogen submitted the same data to the FDA for approval of ADUHELM that had already, in March 2019, showed the drug had insufficient clinical benefit and … Full story available on Benzinga.

NEW YORK, Feb. 14, 2022 /PRNewswire/ -- Attention Biogen Inc. ("Biogen") (NASDAQ: BIIB) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between June 7, 2021 and January 11, 2022. If you suffered a loss…

NEW YORK, Feb. 13, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Biogen, Inc. (NASDAQ: BIIB ), Telos Corporation (NASDAQ: TLS ), Fennec Pharmaceuticals, Inc. (NASDAQ: FENC ), and Astra Space, Inc. (NASDAQ: ASTR ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Biogen, Inc. (NASDAQ: BIIB ) Class Period: June 7, 2021 January 11, 2022 Lead Plaintiff Deadline: April 8, 2022 The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab''s effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding aducanumab''s effectiveness; (3) the PRIME study did not and would not provide necessary data regarding aducanumab''s effectiveness; (4) the data provided by the Company to the FDA''s Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, defendants'' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

The company has several interesting companies on its short list.

The company has several interesting companies on its short list.

SAN DIEGO--(BUSINESS WIRE)---- $BIIB #Alzheimers--Biogen Inc. (BIIB) Misled the Public and Investors Regarding the Viability of its Alzheimer''s Drug Aduhelm

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.